

Alison Laws

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7149429/publications.pdf>

Version: 2024-02-01

24
papers

302
citations

1051969

10
h-index

993246

17
g-index

25
all docs

25
docs citations

25
times ranked

403
citing authors

#	ARTICLE	IF	CITATIONS
1	Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1660-1667.	0.7	14
2	ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision. <i>Annals of Surgical Oncology</i> , 2022, 29, 1668-1669.	0.7	0
3	Abstract P2-13-02: Pathologic nodal staging and systemic therapy among patients with cT1-2N0 HER2+ breast cancer: A prospective single institution cohort analysis. <i>Cancer Research</i> , 2022, 82, P2-13-02-P2-13-02.	0.4	2
4	Abstract P3-04-03: The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study. <i>Cancer Research</i> , 2022, 82, P3-04-03-P3-04-03.	0.4	0
5	Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7726-7736.	0.7	5
6	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227.	1.1	10
7	Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. <i>Modern Pathology</i> , 2021, 34, 875-882.	2.9	18
8	Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community. <i>JCO Oncology Practice</i> , 2021, 17, e217-e225.	1.4	9
9	Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1358-1367.	0.7	29
10	Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer. <i>Oncology</i> , 2021, 35, 77-83.	0.4	7
11	Sentinel Node Biopsy Should Not be Routine in Older Patients with ER-Positive HER2-Negative Breast Cancer Who Are Willing and Able to Take Hormone Therapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 5950-5957.	0.7	17
12	Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 7347-7355.	0.7	6
13	Baseline Screening MRI Uptake and Findings in Women with 20% Lifetime Risk of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3595-3602.	0.7	4
14	Node-Positive Patients Treated with Neoadjuvant Chemotherapy Can Be Spared Axillary Lymph Node Dissection with Wireless Non-Radioactive Localizers. <i>Annals of Surgical Oncology</i> , 2020, 27, 4819-4827.	0.7	32
15	Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques. <i>Current Breast Cancer Reports</i> , 2020, 12, 317-325.	0.5	0
16	Breast Biopsy During Post-treatment Surveillance of Screen-Detected Breast Cancer Patients Yields High Rates of Benign Findings. <i>Annals of Surgical Oncology</i> , 2020, 27, 2689-2697.	0.7	3
17	Improving Wait Times and Patient Experience Through Implementation of a Provincial Expedited Diagnostic Pathway for BI-RADS 5 Breast Lesions. <i>Annals of Surgical Oncology</i> , 2019, 26, 3361-3367.	0.7	7
18	Same-Day Surgery for Mastectomy Patients in Alberta: A Perioperative Care Pathway and Quality Improvement Initiative. <i>Annals of Surgical Oncology</i> , 2019, 26, 3354-3360.	0.7	17

#	ARTICLE	IF	CITATIONS
19	Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3846-3855.	0.7	19
20	Does intraoperative margin assessment improve margin status and reexcision rates? A population-based analysis of outcomes in breast-conserving surgery for ductal carcinoma in situ. <i>Journal of Surgical Oncology</i> , 2018, 118, 1205-1211.	0.8	9
21	“Driving” Rates Down: A Population-Based Study of Opening New Radiation Therapy Centers on the Use of Mastectomy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2994-3003.	0.7	5
22	Implementation of a Venous Thromboembolism Prophylaxis Protocol Using the Caprini Risk Assessment Model in Patients Undergoing Mastectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3548-3555.	0.7	17
23	Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 3541-3547.	0.7	47
24	Intraoperative Margin Assessment in Wire-Localized Breast-Conserving Surgery for Invasive Cancer: A Population-Level Comparison of Techniques. <i>Annals of Surgical Oncology</i> , 2016, 23, 3290-3296.	0.7	23